Kyverna Therapeutics, Inc. Variable Lease, Cost
Kyverna Therapeutics, Inc. (KYTX) reported Variable Lease, Cost of $78.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-11
- Kyverna Therapeutics, Inc. variable lease, cost for the quarter ending 2026-06-30 was $78.00K, a 72.63% decline year-over-year.
- Kyverna Therapeutics, Inc. variable lease, cost for the quarter ending 2026-03-31 was $397.00K, a 36.43% increase year-over-year.
- Kyverna Therapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $120.00K, a 53.49% decline year-over-year.
- Kyverna Therapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $318.00K, a 21.37% increase year-over-year.
- Kyverna Therapeutics, Inc. variable lease, cost for fiscal 2025 was $1.10M, a 2.80% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. variable lease, cost for fiscal 2024 was $1.07M, a 10.52% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. variable lease, cost for fiscal 2023 was $970.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 3 month as first filed | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $78.00K 10-Q · filed 2026-08-11 | $750.00K 10-Q · filed 2026-08-11 | $595.00K derived: sum of 3 quarters · filed 2026-08-11 | $913.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $397.00K 10-Q · filed 2026-05-12 | $517.00K derived: sum of 2 quarters · filed 2026-05-12 | $835.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.12M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $438.00K derived: sum of 2 quarters · filed 2026-03-26 | $723.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.10M 10-K · filed 2026-03-26 | |
| 2025-09-30 | $318.00K 10-Q · filed 2025-11-12 | $603.00K derived: sum of 2 quarters · filed 2026-08-11 | $982.00K 10-Q · filed 2025-11-12 | $1.15M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $285.00K 10-Q · filed 2026-08-11 | $657.00K 10-Q · filed 2026-08-11 | $834.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.10M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $291.00K 10-Q · filed 2026-05-12 | $300.00K 10-Q · filed 2025-05-13 | $549.00K derived: sum of 2 quarters · filed 2026-05-12 | $811.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.07M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $258.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $520.00K derived: sum of 2 quarters · filed 2026-03-26 | $782.00K derived: sum of 3 quarters · filed 2026-03-26 | $1.07M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $262.00K 10-Q · filed 2025-11-12 | $524.00K derived: sum of 2 quarters · filed 2025-11-12 | $814.00K 10-Q · filed 2025-11-12 | $1.06M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $262.00K 10-Q · filed 2025-08-12 | $553.00K 10-Q · filed 2025-08-12 | $802.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.05M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-13 | $291.00K 10-Q · filed 2024-05-14 | $540.00K derived: sum of 2 quarters · filed 2025-05-13 | $786.00K derived: sum of 3 quarters · filed 2025-05-13 | $1.03M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $240.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $486.00K derived: sum of 2 quarters · filed 2025-03-27 | $732.00K derived: sum of 3 quarters · filed 2025-03-27 | $970.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $246.00K 10-Q · filed 2024-11-13 | $492.00K derived: sum of 2 quarters · filed 2024-11-13 | $730.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $246.00K 10-Q · filed 2024-08-12 | $484.00K 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $237.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |